All VCAM1 reagents are produced in house and quality controlled, including 12 VCAM1 Antibody, 48 VCAM1 Gene, 1 VCAM1 IPKit, 5 VCAM1 Lysate, 5 VCAM1 Protein, 3 VCAM1 qPCR. All VCAM1 reagents are ready to use.
Recombinant VCAM1 proteins are expressed by HEK293 Cells with fusion tags as C-human IgG1-Fc, N-His, C-human IgG1-Fc & His, C-His.
VCAM1antibodies are validated with different applications, which are ELISA, WB, ICC/IF, IF, IP, IHC-P.
VCAM1cDNA clones are full length sequence confirmed and expression validated. There are 13 kinds of tags for each VCAM1 of different species, especially GFP tag, OFP tag, FLAG tag and so on. There are three kinds of vectors for choice, cloning vector, expression vector and lentivrial expression vector.
Vascular cell adhesion molecule 1 (VCAM-1), also known as CD106, is a cell surface sialoglycoprotein belonging to the immunoglobulin superfamily. Two forms of VCAM-1 with either six or seven extracellular Ig-like domains are generated by alternative splicing, with the longer form predominant. VCAM-1 is an endothelial ligand for very late antigen-4 (VLA-4) and α4ß7 integrin expressed on leukocytes, and thus mediates leukocyte-endothelial cell adhesion and signal transduction. VCAM-1 expression is induced on endothelial cells during inflammatory bowel disease, atherosclerosis, allograft rejection, infection, and asthmatic responses. During these responses, VCAM-1 forms a scaffold for leukocyte migration. VCAM-1 also activates signals within endothelial cells resulting in the opening of an "endothelial cell gate" through which leukocytes migrate. VCAM-1 has been identified as a potential anti-inflammatory therapeutic target, the hypothesis being that reduced expression of VCAM-1 will slow the development of atherosclerosis. In addition, VCAM-1-activated signals in endothelial cells are regulated by cytokines indicating that it is important to consider both endothelial cell adhesion molecule expression and function during inflammatory processes.